Welcome to Aqualung Therapeutics
Aqualung Therapeutics seeks to introduce new technologies to diagnose, prevent, and treat pulmonary disorders. The current focus is to develop a therapeutic antibody targeting a stretch-induced cytokine released by ventilator-damaged lung cells. Twenty million Americans are placed on mechanical ventilation each year and are potentially at risk to develop acute lung injury, which afflicts 200,000 Americans with 40% mortality. Our therapeutic antibody has been demonstrated in animal models to prevent and treat ventilator-induced lung injury.
Aqualung Therapeutics was founded in December 2010 by Dr. Joe G. N. Garcia, a world-renowned physician-scientist in pulmonary and critical care medicine, to develop novel therapeutic agents discovered by his research laboratory team at the University of Illinois at Chicago (UIC) into clinical therapies for treating acute, subacute, and chronic inflammatory lung injury.
Aqualung Therapeutics is sponsored by or works in conjunction with:
Ventilator Induced Lung Injury or VILI is a type of lung injury caused by mechanical ventilation...
Pre-B-Cell Colony-Enhancing Factor or PBEF, also known as nicotinamide phosphoribosyltransferase (Nampt) or visfatin, is a novel stretch-induced cytokine that contributes to VILI due to mechanical stretch....
Click on image or below link to watch a video demonstrating VILI in a rat lung.